TG Therapeutics Inc (NASDAQ:TGTX) shares, rose in value on Friday, April 05, with the stock price down by -0.55% to the previous day’s close as strong demand from buyers drove the stock to $14.38.
Actively observing the price movement in the recent trading, the stock is buoying the session at $14.46. The value of beta (5-year monthly) is 2.33 whereas the PE ratio is 1019.86 over 12-month period. Referring to stock’s 52-week performance, its high was $35.67, and the low was $6.46. On the whole, TGTX has fluctuated by -21.12% over the past month.
With the market capitalization of TG Therapeutics Inc currently standing at about $2.22 billion, investors are eagerly awaiting this quarter’s results, scheduled for Apr 29, 2024 – May 03, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.04, which is expected to increase to -$0.01 for fiscal year -$0.11 and then to about $0.48 by fiscal year 2025. Data indicates that the EPS growth is expected to be -222.20% in 2025, while the next year’s EPS growth is forecast to be 536.40%.
Analysts have estimated the company’s revenue for the quarter at $54.58 million, with a low estimate of $46 million and a high estimate of $59 million. According to the average forecast, sales growth in current quarter could jump up 599.50%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $263.85 million, representing an increase of 12.90% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that TGTX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of Hold while long term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of TGTX currently trading nearly -7.18% and -6.93% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 38.08, while the 7-day volatility ratio is showing 3.44% which for the 30-day chart, stands at 4.51%. Furthermore, TG Therapeutics Inc (TGTX)’s beta value is 2.32, and its average true range (ATR) is 0.70.
A comparison of TG Therapeutics Inc (TGTX) with its peers suggests the former has fared considerably weaker in the market. TGTX showed an intraday change of -0.55% in today’s session so far, and over the past year, it shrunk by -12.48%%.
Data on historical trading for TG Therapeutics Inc (NASDAQ:TGTX) indicates that the trading volumes over the past 10 days have averaged 2.23 million and over the past 3 months, they’ve averaged 4.44 million. According to company’s latest data on outstanding shares, there are 151.42 million shares outstanding.
Nearly 9.75% of TG Therapeutics Inc’s shares belong to company insiders and institutional investors own 58.94% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 34.19 million shares as on Mar 15, 2024, resulting in a short ratio of 7.69. According to the data, the short interest in TG Therapeutics Inc (TGTX) stood at 22.14% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 35.78 million. The stock has fallen by -15.81% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TGTX stock heading into the next quarter.
